Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. (Q34556808)

3 August 2017

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. (English)

1 reference

3 August 2017

1 reference

Kim JH

1

1 reference

3 August 2017

Oh JY

2

1 reference

3 August 2017

Park BH

3

1 reference

3 August 2017

Lee DE

4

1 reference

3 August 2017

Kim JS

5

1 reference

3 August 2017

Park HE

6

1 reference

3 August 2017

Roh MS

7

1 reference

3 August 2017

Je JE

8

1 reference

3 August 2017

Yoon JH

9

1 reference

3 August 2017

Thorne SH

10

1 reference

3 August 2017

Kirn D

11

1 reference

3 August 2017

Hwang TH

12

1 reference

3 August 2017

1 September 2006

1 reference

3 August 2017

1 reference

3 August 2017

14

1 reference

3 August 2017

3

1 reference

3 August 2017

361-370

1 reference

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Replicating vectors for gene therapy of cancer: risks, limitations and prospects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Recent progress in the battle between oncolytic viruses and tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

GM-CSF-secreting melanoma vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Poxvirus vectors: orphaned and underappreciated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Modeling and analysis of a virus that replicates selectively in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Systemic therapy of myeloma xenografts by an attenuated measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.05.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2006.05.008

1 reference

3 August 2017

1 reference